Provisional Patent Application Filed for AI-Guided Bioelectric Enhanced Regenerative Dentistry System
Huntington Beach, California – [Date] — Lionheart Health, Inc. today announced the unveiling of DentaCell™, a next-generation regenerative dentistry platform that combines personalized bioelectric stimulation, regenerative biologics, artificial intelligence, advanced digital dentistry, and precision treatment planning to support regeneration of periodontal tissues, gingiva, alveolar bone, oral soft tissues, and improved long-term oral health.
The company also announced the filing of a provisional patent application covering multiple embodiments of the DentaCell™ platform, including AI-guided treatment planning, personalized bioelectric stimulation protocols, bioelectric enhancement of regenerative biologics, intelligent treatment monitoring, and custom 3D-printed therapeutic delivery systems.
“Dentistry is entering an era where regeneration can become personalized. Rather than relying on a single material or biologic, DentaCell™ is being designed as an intelligent platform that integrates bioelectric medicine, regenerative biologics, AI, digital imaging, and personalized treatment delivery to help optimize healing for each individual patient.”
— Howard J. Leonhardt
Executive Chairman & Co-CEO
Lionheart Health, Inc.
A Personalized Regenerative Dentistry Platform
DentaCell™ is being developed as a comprehensive regenerative platform intended to combine:
Personalized bioelectric stimulation
AI-driven treatment planning
Bioelectric-enhanced regenerative biologics
Platelet-Rich Fibrin (PRF)
Injectable PRF
BioPRF™
Stromal Vascular Fraction (SVF)
Bone Marrow Concentrate (BMAC)
Stem cell homing technologies
Digital treatment planning
3D printed patient-specific treatment appliances
Remote treatment monitoring
Unlike conventional regenerative dental products that primarily utilize scaffold materials or isolated biologics, DentaCell™ is intended to integrate multiple regenerative technologies into one personalized therapeutic system.
Artificial Intelligence Personalization
The DentaCell™ software platform is intended to analyze:
CBCT scans
Intraoral digital scans
Digital impressions
Bone quality
Periodontal pocket depth
Gingival recession
Tooth stability
Occlusion
Bite-force measurements
Oral photographs
Healing progress
Medical history
Age
Inflammatory biomarkers
Salivary biomarkers
Previous treatment response
Using these inputs, the AI platform is intended to recommend individualized bioelectric treatment parameters and regenerative biologic combinations tailored to each patient’s clinical presentation.
Bioelectric Protein Expression Programming
A core component of DentaCell™ is Lionheart Health’s ongoing research into proprietary bioelectric stimulation waveforms designed to influence cellular signaling pathways associated with tissue repair and regeneration. These investigational protocols are being explored for their potential to encourage expression of proteins involved in healing.
Research targets include:
Stem Cell Recruitment
SDF-1 (CXCL12)
PDGF
CXCR4 signaling
Blood Vessel Formation
VEGF
eNOS
HIF-1α
Bone Regeneration
BMP-9
RUNX2
Osteocalcin
Alkaline Phosphatase
Bone Remodeling
Osteoprotegerin (OPG)
Balanced RANKL/OPG signaling
Healthy Tissue Remodeling
Tropoelastin
COL17A1
Collagen remodeling pathways
Healthy Aging Biology
Klotho
Sestrins
Sirtuins
Apelin
Bioelectric Enhanced Regenerative Biologics
DentaCell™ is also being developed to combine bioelectric stimulation with regenerative biologic therapies before, during, and following treatment.
Potential biologic combinations under investigation include:
Platelet-Rich Fibrin (PRF)
Injectable PRF
BioPRF™
Stromal Vascular Fraction
Bone Marrow Concentrate
Exosomes
Secretome products
Placental-derived biologics
Peptide therapies where permitted by applicable regulations
The objective is to support cellular recruitment, vascularization, tissue integration, and healing.
Intelligent 3D Printed Treatment Appliances
Future embodiments described in the provisional patent application include custom patient-specific oral appliances manufactured from digital scans.
Potential features include:
Precision electrode positioning
Integrated light therapy channels
Bioelectric treatment delivery
Medication reservoirs
Pressure optimization
Bite-force sensors
Treatment verification sensors
Wireless treatment monitoring
Cloud-connected treatment updates
Clinical Applications Under Development
DentaCell™ is being designed for future investigation across numerous regenerative dentistry applications, including:
Periodontal regeneration
Gingival tissue restoration
Alveolar bone regeneration
Bone graft enhancement
Dental implant site preparation
Implant integration support
Tooth extraction healing
Socket preservation
Guided tissue regeneration
Oral wound healing
Cosmetic soft tissue enhancement
Peri-implant tissue health
Oral surgery recovery
Jaw bone preservation
TMJ supportive therapies
Future Platform Expansion
Future embodiments described in the provisional patent application also include potential integration with:
Near-infrared photobiomodulation
Red light therapy
Pulsed electromagnetic field therapy (PEMF)
Acoustic stimulation
Mechanical micro-vibration
Salivary biomarker analysis
Cloud-based AI optimization
Remote physician monitoring
Longitudinal digital treatment tracking
Research and Development
DentaCell™ is currently in research and development. Lionheart Health intends to pursue laboratory studies, preclinical validation, and future clinical investigations to evaluate safety and performance. Any references to modulation of protein expression, regenerative activity, or anticipated clinical applications describe investigational objectives and should not be interpreted as established clinical outcomes.
About Lionheart Health
Lionheart Health, Inc. is developing bioelectric medicine technologies intended to advance regenerative medicine, longevity science, aesthetics, cardiovascular health, musculoskeletal medicine, neurological wellness, sexual health, vision, hearing, oral regeneration, and other emerging applications. The company’s technology platform combines precision bioelectric stimulation, regenerative biologics, artificial intelligence, and personalized treatment delivery across more than 25 investigational therapeutic programs.
Media Contact
Howard J. Leonhardt
Executive Chairman & Co-CEO
Lionheart Health, Inc.
www.LionheartHealthStim.com
www.LionheartLongevity.com
Forward-Looking Statements
This press release contains forward-looking statements regarding technologies under development. DentaCell™ is an investigational platform www.DentaCellAccelerator.com and has not received regulatory clearance or approval. Statements regarding anticipated capabilities, future applications, or potential clinical benefits reflect research and development objectives and should not be interpreted as evidence of established safety or effectiveness.